Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTE NYSE:MBX NASDAQ:SBTX NASDAQ:TOCA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTEAerovate Therapeutics$7.90-2.2%$8.61$56.35▼$105.00$228.98M0.9512,438 shs47,960 shsMBXMBX Biosciences$15.09+5.7%$13.06$4.81▼$27.50$506.93MN/A324,882 shs154,165 shsSBTXSilverback Therapeutics$11.62-9.6%$16.54$2.80▼$8.97$418.99M0.6337,931 shs7.18 million shsTOCATocagen$11.00-2.0%$32.24$0.42▼$6.77$263.11M0.011.47 million shs177,688 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTEAerovate Therapeutics0.00%-4.01%+14.66%+9.72%-88.30%MBXMBX Biosciences0.00%+8.64%+9.75%+10.47%+1,508,999,900.00%SBTXSilverback Therapeutics0.00%-13.93%-32.36%-19.64%-10.48%TOCATocagen0.00%-3.76%+14.46%+24.58%+39.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMBXMBX Biosciences2.1519 of 5 stars3.50.00.00.02.11.70.6SBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTEAerovate Therapeutics 0.00N/AN/AN/AMBXMBX Biosciences 3.00Buy$37.63149.34% UpsideSBTXSilverback Therapeutics 0.00N/AN/AN/ATOCATocagen 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest TOCA, MBX, SBTX, and AVTE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/ATOCATocagen$40K6,577.73N/AN/A$0.45 per share24.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%11/10/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ATOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTEAerovate TherapeuticsN/A8.788.78MBXMBX BiosciencesN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87TOCATocagen1.881.151.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTEAerovate TherapeuticsN/AMBXMBX BiosciencesN/ASBTXSilverback Therapeutics74.89%TOCATocagen21.42%Insider OwnershipCompanyInsider OwnershipAVTEAerovate Therapeutics24.90%MBXMBX Biosciences52.19%SBTXSilverback Therapeutics34.40%TOCATocagen10.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/ASBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableTOCATocagen7723.92 millionN/ANot OptionableTOCA, MBX, SBTX, and AVTE HeadlinesRecent News About These CompaniesTocagen plummets on phase 3 data for glioma therapyFebruary 2, 2025 | pharmaphorum.comPCelgene hopes device + drug can tackle aggressive brain tumoursSeptember 18, 2024 | pharmaphorum.comPForte Biosciences Inc (FBRX)August 7, 2024 | investing.comAnova to Manage Study of DB107 Following Newly Awarded $11.8M CIRM GrantMay 1, 2024 | finance.yahoo.comGlioblastoma Treatment Market Expected to Reach USD 10.3 Billion by 2032 | Marketresearch.bizMarch 25, 2024 | pharmiweb.comPONC201 (Dordaviprone) in Recurrent H3 K27M–Mutant Diffuse Midline GliomaFebruary 12, 2024 | ascopubs.orgAMiami Cancer Institute publication analyzes role of tissue-agnostic therapies for the treatment of primary brain tumorsJanuary 19, 2024 | eurekalert.orgEForte Biosciences: Changes In Registrant S Certifying AccountantDecember 12, 2023 | cbonds.comCRiskOn International And 3 Other Stocks Under $2 Insiders Are BuyingDecember 11, 2023 | markets.businessinsider.comPrecision and personalized medicine: the leading companies in personalized cancer vaccines revealedNovember 6, 2023 | pharmaceutical-technology.comPProfoundBio Readies for Next Phase of Growth with Management Team Additions and Advisory Board AppointmentNovember 2, 2023 | finance.yahoo.comFDA Clears Phase II Trial of Denovo Biopharma Gene Therapy in Glioma PatientsJuly 26, 2023 | precisionmedicineonline.comPGene Therapy Market Report 2023 Provides SWOT Analysis ... - openPRMay 12, 2023 | news.google.comNForm DEF 14A CTI BIOPHARMA CORP For: Jun 21 - StreetInsider.comApril 28, 2023 | news.google.comNGenomic and transcriptomic analysis of checkpoint blockade ... - Nature.comApril 6, 2023 | news.google.comNBelzutifan plus cabozantinib for patients with advanced clear cell ... - The LancetMarch 31, 2023 | news.google.comNCurrent drug development and trial designs in neuro-oncology ... - The LancetMarch 27, 2023 | news.google.comNCompanion Diagnostics Market is set to experience a significant ... - Digital JournalMarch 27, 2023 | news.google.comNOligodendroglioma Pipeline Drugs and Companies Insight Report ... - Digital JournalMarch 14, 2023 | news.google.comNAnaplastic Astrocytoma Drug Market| Global Industry Analysis ... - Digital JournalMarch 8, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTOCA, MBX, SBTX, and AVTE Company DescriptionsAerovate Therapeutics NASDAQ:AVTE$7.90 -0.18 (-2.23%) As of 08/29/2025Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.MBX Biosciences NYSE:MBX$15.09 +0.82 (+5.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.04 -0.05 (-0.33%) As of 08/29/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Silverback Therapeutics NASDAQ:SBTX$11.62 -1.24 (-9.64%) As of 08/29/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Tocagen NASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
